PMA device
Adapta
Medtronic, Inc. · Pulse Generator, Permanent, Implantable (NVZ, Class III) · First FDA decision Feb 14, 2014, newest Dec 22, 2020Bradycardia and heart blockHeart failure
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
4
PMA pathway
Device trials
3
Naming "Adapta"
MAUDE reports
7,876
Brand "Adapta", since 2015
PubMed studies
40
Mentioning "Adapta"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Adapta
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 4 of 4 decisions filed under this name.
- Adapta, Versa, Sensia IPG, Astra S DR MRI IPG, Astra S SR MRI IPG, Astra XT DR MRI IPG, Astra XT SR MRI IPG, Attesta DRPMA supplement
P980035-S667 · Decided Dec 22, 2020 · 19 days after receipt · Normal 180 Day Track No User Fee
Device type: Pulse generator, permanent, implantable (NVZ) · Cardiology
- Adapta, Versa, Sensia IPG, Software application, Attesta DR MRI IPG, Attesta SR MRI IPG, Relia IPG, Sphera DR MRI IPG,PMA supplement
P980035-S594 · Decided Aug 20, 2019 · 90 days after receipt · Normal 180 Day Track
Device type: Pulse generator, permanent, implantable (NVZ) · Cardiology
- ADAPTA, VERSA, SENSIA IPG. ADVISA DR IPG, ADVISA DR MRI IPG, ADVISA SR MRI IPG, ENOUKSE E2 IOG, KAPPA D IPG,KAPPA DR IPPMA supplement
P980035-S447 · Decided May 3, 2016 · 154 days after receipt · Normal 180 Day Track
Device type: Pulse generator, permanent, implantable (NVZ) · Cardiology
1 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Adapta", any status and sponsor, newest update first.
- A Comparison of the Pacemaker Automatic Features in Reduction of Ventricular PacingPivotal-lookingCompleted
Medtronic Cardiac Rhythm and Heart FailurePublic (MDT)
NCT01039467 · 385 participants · Start Jun 2009 · Primary completion Apr 2014
Device: Medtronic Adapta Dual Chamber Pacemaker · For: Bradycardia
Sites: Beijing, China; Fuzhou, China; Guangzhou, China · 30 sites in all
Mayo ClinicAcademic, hospital or other
NCT00589303 · 27 participants · Start Dec 2007 · Primary completion Jul 2011
Device: AV Node ablation and device implant · For: Atrial Fibrillation; Heart Failure
Sites: Scottsdale, Arizona; Evansville, Indiana; Rochester, Minnesota · 6 sites in all
- Adapta Pacing System Clinical StudyPivotal-lookingCompleted
Medtronic Cardiac Rhythm and Heart FailurePublic (MDT)
NCT00307073 · 120 participants · Start May 2005
Device: Implantable Pulse Generator · For: Pacemaker; Bradycardia
Sites: Graz, Austria; Prague, Czechia; Bad Nauheim, Germany · 7 sites in all
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Adapta", and for the whole product code for context.
This brand
7,876 reports: 2,710 malfunction, 4,715 injury, 451 death
Whole product code NVZ
72,953 reports: 32,608 malfunction, 38,411 injury, 1,913 death
Newest reports for this brand
- AdaptaMalfunction
3004209178-2026-18360 · Received Oct 28, 2026 · Event dated Oct 1, 2026
Device type: Pulse Generator, Permanent, Implantable (NVZ)
Device problem as coded: Failure to Interrogate; Appropriate Device Problem Term/Code Not Available
Patient problem as coded: Bradycardia
- AdaptaInjury
3004209178-2026-18389 · Received Oct 28, 2026 · Event dated Jun 12, 2026
Device type: Pulse Generator, Permanent, Implantable (NVZ)
Device problem as coded: Electrical /Electronic Property Problem
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- AdaptaInjury
3004209178-2026-18399 · Received Oct 28, 2026 · Event dated Sep 29, 2026
Device type: Pulse Generator, Permanent, Implantable (NVZ)
Device problem as coded: Electromagnetic Interference; Pacing Problem
Patient problem as coded: Asystole
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-2127-2025 · Started Jun 17, 2025 · Posted by FDA Jul 17, 2025
Reason given: A software update for Medtronic CareLink SmartSync Device Manager (SmartSync) is now available. The update eliminates the potential display of an erroneous electrical reset (pop-up) message upon interrogation with a SmartSync Device Manager. The erroneous message indicates an electrical reset has occurred. However, no...
Cause as FDA categorized it: Software design · Device type: Programmer, Pacemaker (KRG)
Z-2128-2025 · Started Jun 17, 2025 · Posted by FDA Jul 17, 2025
Reason given: A software update for Medtronic CareLink SmartSync Device Manager (SmartSync) is now available. The update eliminates the potential display of an erroneous electrical reset (pop-up) message upon interrogation with a SmartSync Device Manager. The erroneous message indicates an electrical reset has occurred. However, no...
Cause as FDA categorized it: Software design · Device type: Programmer, Pacemaker (KRG)
- Azure S DR MRI SureScan, Product number W3DR01Open, Classified
Z-1924-2025 · Started Apr 29, 2025 · Posted by FDA Jun 6, 2025
Reason given: Identified devices may experience sudden battery power failure without alarm, power supply power-on-resets, and interruption of therapy. Potential patient harms include insufficient pacing support leading to cardiac arrest, syncope, or hospitalization; or system revision (explant/replacement) leading to infection,...
Cause as FDA categorized it: Process change control · Device type: Pulse Generator, Permanent, Implantable (NVZ)
13 more recall records with a free account
Published research
The most relevant PubMed records for "Adapta"[tiab]. The summary above synthesizes these.
- [Qualitative evaluation of a participatory process of adaptation of a health promotion guide.].
Calvo Martínez MJ, Ruiz Peralta E, Cassetti V, et al. · Rev Esp Salud Publica · 2021
- Discovery of Novel PI3Kδ Inhibitors Based on the p110δ Crystal Structure.
Jia W, Luo S, Zhao W, et al. · Molecules · 2022
- Assessing treatment benefit in the presence of placebo response using the sequential parallel comparison design.
Liu X, Kim C, Han Z, et al. · Stat Med · 2022Research Support, Non-U.S. Gov't
- Adaptation to Change Questionnaire for Nurses: Validation and New Needs in the Context of COVID-19.
Barragán Martín AB, Molero Jurado MDM, Pérez-Fuentes MDC, et al. · Healthcare (Basel) · 2021
- Adjuvant Chemotherapy After Curative Intent Resection of Ampullary Cancer (ADAPTA): Study Protocol for a Pan-European Prospective Multicenter Double Single Arm Trial.
Uijterwijk BA, Lemmers DHL, Klei DS, et al. · Am J Clin Oncol · 2026Clinical Trial Protocol, Research Support, Non-U.S. Gov't
- Human motor adaptation in whole body motion.
Babič J, Oztop E, Kawato M · Sci Rep · 2016Research Support, Non-U.S. Gov't
- Design and Validation of the Adaptation to Change Questionnaire: New Realities in Times of COVID-19.
Pérez-Fuentes MDC, Molero Jurado MDM, Martos Martínez Á, et al. · Int J Environ Res Public Health · 2020Validation Study
- Group-walk: a rigorous approach to group-wise false discovery rate analysis by target-decoy competition.
Freestone J, Short T, Noble WS, et al. · Bioinformatics · 2022Research Support, Non-U.S. Gov't
- Influence of yeast adaptation with bio-activators on the process of wine alcoholic fermentation.
Viola E, Naselli V, Craparo V, et al. · Food Microbiol · 2025
- Disentangling protein and lipid interactions that control a molecular switch in photosynthetic light harvesting.
Crisafi E, Pandit A · Biochim Biophys Acta Biomembr · 2017Research Support, Non-U.S. Gov't
- ADAPTA: A pilot randomised controlled trial of an alcohol-focused intervention versus a healthy living intervention for problem drinkers identified in a general hospital setting.
Watson JM, Fairhurst C, Li J, et al. · Drug Alcohol Depend · 2015Randomized Controlled Trial, Pragmatic Clinical Trial
- Effect of Removable Complete Dentures on the Fundamental Frequency of Speech.
Hussein M, Hristov I · Folia Med (Plovdiv) · 2020
Other devices of this type
Also filed under product code NVZ.
- CareLink Instruments & DDMA, CareLink SmartSync Common ApplicationMedtronic, Inc. · PMA 2023
- Affinity/Integrity/Victory/Zephyr/Accent Family of PacemakersAbbott Medical · PMA 2016
- Adapta, Versa, Sensia IPGEnPulse E1 IPG Kappa DR (Kappa 700/600)Medtronic, Inc. · PMA 2017
- Various Families of PacemakersMedtronic, Inc. · PMA 2008
- Cadence Family of IcdsAbbott Medical · PMA 2012
- Medtronic CareLink Monitor, CardioSight ReaderMedtronic, Inc. · PMA 2019
- Legend Plus Family of PacemakersMedtronic, Inc. · PMA 2011
- Advisa DR MRI SureScan Model A2DR01 IPG, Advisa SR MRI SureScan Model A3SR01 IPGMedtronic, Inc. · PMA 2022
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.